Sintesis dan Uji Aktivitas Penghambatan Terhadap Enzim α-Glukosidase untuk Amida dari Asam 5-bromofuran-2-karboksilat dan Asam furan-3-karboksilat

Maghfiroh, Reyza Fadly (2023) Sintesis dan Uji Aktivitas Penghambatan Terhadap Enzim α-Glukosidase untuk Amida dari Asam 5-bromofuran-2-karboksilat dan Asam furan-3-karboksilat. Other thesis, Institut Teknologi Sepuluh Nopember.

Text 01211940000043-Undergraduate_Thesis.pdf - Accepted Version Restricted to Repository staff only until 1 September 2025. Download (3MB) | Request a copy

Abstract

terdapat 451 juta jiwa terjangkit diabetes melitus di dunia pada tahun 2017, dan diperkirakan mencapai 693 juta jiwa pada tahun 2045. Organisasi Kesehatan Dunia (WHO) mengemukakan bahwa 71% penyebab kematian adalah penyakit tidak menular, dan diabetes menjadi salah satu penyumbang tertinggi pada tahun 2018 (tercatat terdapat 2,2 juta jiwa yang meninggal akibat diabetes melitus). Diabetes tipe II merupakan tipe diabetes yang paling umum dijumpai (90-95%). Obat diabetes tipe II komersial berperan menghambat enzim α-glukosidase; tetapi mempunyai efek samping berupa gangguan pencernaan, diare, dan toksik pada hati. Furan karboksamida menunjukkan bioaktivitas menghambat enzim α-glukosidase, tetapi metoda sintesis furan karboksamida melibatkan pereaksi-pereaksi berbahaya atau memberikan hasil samping yang toksik. Permasalahan yang diangkat dalam penelitian adalah bagaimana mengembangkan metoda sintesis dan mendapatkan furan karboksamida sebagai inhibitor enzim α-glukosidase yang lebih efektif dari pada obat komersial. Penelitian yang dilakukan berhasil mengembangkan metoda sintesis furan karboksamida, yang diterapkan untuk furan karboksamida (34a-b). Kedua senyawa masing-masing diperoleh dengan rendemen 69% dan 83%, serta keduanya mampu menghambat enzim α-glukosidase yang lebih baik dari pada obat komersial akarbosa (IC50 sebesar 189,00±9,4 μM). Senyawa (34b) menunjukkan bioaktivitas penghambatan terhadap enzim α-glukosidase yang lebih baik dari pada senyawa (34a), dengan IC50 sebesar 86,63±0,04 μM.
====================================================================================================================================
International Diabetes Federation (IDF) estimates that there were 451 million people affected by diabetes mellitus in the world in 2017, and is expected to reach 693 million people by 2045. World Health Organization (WHO) suggests that 71% of the causes of death are non-communicable diseases, and diabetes is one of the highest contributors in 2018 (there were 2.2 million people who died from diabetes mellitus). Type II diabetes is the most common type of diabetes (90-95%). Commercial type II diabetes drugs inhibit the α-glucosidase enzyme; however, they have side effects such as indigestion, diarrhea, and are toxic to the liver. Furan carboxamide shows bioactivity in inhibiting α-glucosidase enzyme, but the synthesis method of furan carboxamide involves hazardous reagents or gives toxic by-products. The problem raised in the research is how to develop a synthesis method and obtain furan carboxamide as an α-glucosidase enzyme inhibitor that is more effective than commercial drugs. The research successfully developed a synthesis method of furan carboxamide, which was applied to furan carboxamide (34a-b). Both compounds were obtained with yields of 69% and 83%, respectively, and both were able to inhibit α-glucosidase enzyme better than the commercial drug acarbose (IC50 was 189.00±9.4 μM). Compound (34b) showed better α-glucosidase inhibitory bioactivity with IC50 was 86.63±0.04 μM.

Item Type:	Thesis (Other)
Uncontrolled Keywords:	α-Glucosidase, Furan carboxamide, Synthesis; α-Glukosidase, Furan karboksamida, Sintesis
Subjects:	Q Science > QD Chemistry > QD251.2 Chemistry, Organic. Biochemistry
Divisions:	Faculty of Science and Data Analytics (SCIENTICS) > Chemistry > 47201-(S1) Undergraduate Thesis
Depositing User:	Reyza Fadly Maghfiroh
Date Deposited:	04 Oct 2023 00:56
Last Modified:	04 Oct 2023 00:56
URI:	http://repository.its.ac.id/id/eprint/103794

Actions (login required)

View Item